Table 1. Baseline characteristics of interview participants.
| Characteristic (n=12) | Value |
|---|---|
| Male Sex, n (%) | 8 (67) |
| Age in years, mean±SD | 57±10 |
| Body mass index in kg/m2, mean±SD | 39.4±7.3 |
| Body weight in kg, mean±SD | 120.1±31.3 |
| Cardiorespiratory fitness | |
| in mL/kg/min, mean±SD | 20.9±9.1 |
| Percentile, median (range) | 7th (5th–73rd) |
| Exercise capacity (time on test in seconds), mean±SD | 626.0±178.6 |
| Respiratory exchange ratio at peak capacity | 1.1 (0.1) |
| NAFLD activity score, median (range) | 5 (3–7) |
| Fibrosis, median (range) | 2 (1a–4) |
| F0/1, n (%) | 2 (17) |
| F2, n (%) | 5 (41) |
| F3, n (%) | 3 (25) |
| F4, n (%) | 2 (17) |
| Comorbidities, median (range) | 6 (2–14) |
| Type 2 diabetes, n (%) | 9 (75) |
| Metabolic syndrome, n (%) | 12 (100) |
| Hypertension, n (%) | 11 (92) |
| Musculoskeletal conditions, n (%) | 12 (100) |
| 0 | 0 (0) |
| 1 | 5 (42) |
| 2–3 | 6 (50) |
| >3 | 1 (8) |
| Fatigue domain-CLDQ, mean±SD score/7# | 4.3±1.1 |
| Body pain-CLDQ, mean±SD score/7# | 2.8±1.2 |
| Medications prescribed | |
| Total number of prescribed medications, median (range) | 8 (2–28) |
| Anti-hyperglycemic | 8 (67%) |
| Insulin | 4 (33%) |
| Biguanide | 8 (67%) |
| Sulfonylurea | 2 (17%) |
| DPP-4 inhibitor | 1 (8%) |
| SGLT2 inhibitor | 6 (50%) |
| Antihypertensive | 10 (83%) |
| Cholesterol/lipid lowering | 10 (83%) |
| Beta-blocker | 4 (33%) |
, cardiorespiratory fitness (peak rate of oxygen consumption); percentiles are based on age- and sex-specific cutoffs; #Mean score from CLDQ refers to that experienced in the previous 2 weeks. Responses are a Likert scale ranging from 1 (most impairment) to 7 (least impairment). The fatigue domain comprises an average of five questions. Body pain relates to a single question within the broader systemic symptom domain. NAFLD activity score ranges from 0–8 with ≥ 5 considered more severe disease. CLDQ, chronic liver disease questionnaire; DPP-4, dipeptidyl peptidase-4; NAFLD, nonalcoholic fatty liver disease; SD, standard deviation; SGLT2, sodium-glucose cotransporter-2.